Dr Lal PathLabs

November 04, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Symbol: LALPATHLAB

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 539524

**Sub: Press Release on Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2026**

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2026.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

**For Dr. Lal PathLabs Limited**

Vinay Gujral
Digitally signed by Vinay Gujral
Date: 2026.11.04 13:56:23 +05'30'

**Vinay Gujral**
**Company Secretary & Compliance Officer**

*Encl.: As above*



Classification: Internal

For Immediate Release

November 4, 2026

**Dr Lal PathLabs Limited records revenue of Rs 874 Cr with a growth of 19.6% in Q2 FY27**

**New Delhi, India, November 4, 2026** – Dr Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2026.

**Consolidated Performance Highlights: Q2 FY27**

- Revenue increased by 19.6% in Q2 FY27 and 19.4% in H1 FY27.
- EBITDA for Q2 FY27 increased by 25.1% with a margin of 32.1%
- EBITDA for H1 FY27 increased by 26.7% with a margin of 31.6%
- PAT for Q2 FY27 is Rs 194 Cr. increased by 27.5% with a margin for of 22.2%
- PAT for H1 FY27 is Rs 364 Cr. increased by 27.3% with a margin for of 21.8%
- Interim Dividend of 50% i.e. Rs. 5 per share.
- Cash and Cash equivalents as on 30th September 2026 is Rs. 1,746 Cr.

## Financial Overview (Consolidated) in Rs Cr

| Particulars | Q2 | | | FH | | |
|---|---|---|---|---|---|---|
| | FY27 | FY26 | Gr % | FY27 | FY26 | Gr % |
| **Revenue** | **874** | **731** | *19.6%* | **1,672** | **1,400** | *19.4%* |
| Material consumed | 162 | 142 | | 314 | 271 | |
| Employee benefit Expenses | 139 | 124 | | 271 | 248 | |
| Fees to collection centres | 129 | 109 | | 245 | 204 | |
| Other Expenses | 164 | 132 | | 314 | 261 | |
| **Total Expenses** | **594** | **507** | *17.2%* | **1,144** | **984** | *16.3%* |
| **EBITDA** | **280** | **224** | *25.1%* | **528** | **416** | *26.7%* |
| *Margins* | *32.1%* | *30.7%* | | *31.6%* | *29.7%* | |
| Other Income | 34 | 25 | | 66 | 53 | |
| Depreciation Cost | 47 | 41 | | 91 | 75 | |
| Finance Cost | 7 | 5 | | 13 | 9 | |
| **PBT** | **261** | **204** | *28.1%* | **489** | **385** | *27.2%* |
| *Margins* | *29.8%* | *27.9%* | | *29.3%* | *27.5%* | |
| Income Tax | 67 | 51 | | 125 | 98 | |
| **PAT** | **194** | **152** | *27.5%* | **364** | **286** | *27.3%* |
| *Margins* | *22.2%* | *20.8%* | | *21.8%* | *20.4%* | |
| **EPS** | **11.5** | **9.0** | *27.5%* | **21.7** | **17.0** | *27.6%* |

## About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2026 the company has 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 7,727 Patient Service Centers (PSCs) and 13,935 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

## Contact Details


Ved Goel
Group Chief Financial Officer &
CEO- International Business
*Dr Lal PathLabs Limited*
+91 124 3016500
cfo@lalpathlabs.com

Kritika Khatwani
*Adfactors PR*
+91 8604801332
*kritika.khatwani@adfactorspr.com*


For further information on Dr Lal PathLabs see www.lalpathlabs.com

## Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.